CDK7-IN-26
CDK7-IN-26 (compound 36) is an orally active CDK7 inhibitor (IC50: 7.4 nM) . CDK7-IN-26 potently inhibits the growth of triple-negative breast cancer (TNBC) cell line-derived xenograft (CDX) tumors in vivo and inhibits MDA-MB-453 cells in vitro with an IC50 of 0.15 μM[1].
Product Specifications
CAS Number
3024545-79-4
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cdk7-in-26.html
Solubility
10 mM in DMSO
Smiles
O=P(C)(C1=C(C=CC2=C1NC=C2C3=NC(N[C@H]4C[C@H](F)CNC4)=NC5=C3SC=C5)C#N)C
Molecular Formula
C22H22FN6OPS
Molecular Weight
468.49
References & Citations
[1]Zhang H et al. Discovery and optimization of thieno [3, 2-d] pyrimidine derivatives as highly selective inhibitors of cyclin-dependent kinase 7[J]. European Journal of Medicinal Chemistry, 2023: 115955.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
P6735 100 Tests
Protease Inhibitor Cocktail for Purification of His-Tagged Proteins, 100X
Sign In for Pricing
View Details 
